|
Market Closed -
Euronext Paris
19:55:00 02/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.7000 EUR | -1.96% |
|
-7.89% | -27.08% |
| 09-25 | Transgene provides update on its operations |  |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
Company Valuation: Transgene
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.8 | 164.8 | 137.8 | 89.75 | 262.9 | 191.7 | - | - |
| Change | - | -33.52% | -16.38% | -34.86% | 192.89% | -27.07% | - | - |
| Enterprise Value (EV) 1 | 214.9 | 151.4 | 139.4 | 83.48 | 153.1 | 122.5 | 184 | 210.3 |
| Change | - | -29.53% | -7.95% | -40.12% | 83.37% | -19.96% | 50.2% | 14.29% |
| P/E | -12.1x | -5.02x | -6.23x | -2.34x | -3.69x | -5x | -3.18x | -7.78x |
| PBR | 3.69x | 4.38x | 8.82x | 5.92x | 1.14x | 2.33x | 8.75x | -70x |
| PEG | - | -0.1x | 0.2x | -0.1x | 0.4x | 0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | 14.2x | 15.9x | 17.4x | 14.1x | 36.5x | 26.6x | 26.6x | 3.35x |
| EV / Revenue | 12.3x | 14.6x | 17.6x | 13.1x | 21.2x | 17x | 25.6x | 3.68x |
| EV / EBITDA | -10.2x | -5.37x | -4.9x | -2.43x | -4.54x | -2.81x | -2.63x | -8.91x |
| EV / EBIT | -9.14x | -5.06x | -4.64x | -2.34x | -4.37x | -2.77x | -2.6x | -7.18x |
| EV / FCF | -6.59x | -6.94x | -1,408x | -3.12x | -1.07x | -3.09x | -3.05x | -8.38x |
| FCF Yield | -15.2% | -14.4% | -0.07% | -32% | -93.4% | -32.4% | -32.8% | -11.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.14 | -0.22 | -0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 17.41 | 10.34 | 7.9 | 6.353 | 7.21 | 7.2 | 7.2 | 57.2 |
| EBITDA 1 | -21 | -28.22 | -28.48 | -34.38 | -33.73 | -43.6 | -70.1 | -23.6 |
| EBIT 1 | -23.52 | -29.9 | -30.05 | -35.66 | -35.06 | -44.3 | -70.8 | -29.3 |
| Net income 1 | -19.54 | -32.8 | -22.33 | -33.97 | -37.52 | -38.2 | -61.6 | -25.3 |
| Net Debt 1 | -32.93 | -13.31 | 1.629 | -6.274 | -109.8 | -69.2 | -7.7 | 18.6 |
| Reference price 2 | 2.5400 | 1.6580 | 1.3700 | 0.6800 | 0.9600 | 0.7000 | 0.7000 | 0.7000 |
| Nbr of stocks (in thousands) | 97,576 | 99,370 | 100,566 | 131,990 | 273,827 | 273,882 | - | - |
| Announcement Date | 16/03/22 | 16/03/23 | 27/03/24 | 27/03/25 | 24/03/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5x | 17.02x | -2.81x | - | 216M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.38x | 29.93x | 10.94x | 0.31% | 39.07B | |
| Weighted average by Cap. | 22.26x | 32.03x | 13.54x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TNG Stock
- Valuation Transgene
Select your edition
All financial news and data tailored to specific country editions
